BPIQ Elite/APEX Investor Posts

Explore BPIQ’s July 2026 biopharma hedge fund stock picks, $COGT, $IRON, and $TENX, and the key regulatory, Phase 3, and pipeline catalysts ahead.

The bio/pharma IPO market reopened in H1 2026, as we predicted based on the bullish public bio/pharma market starting in the 2nd half of 2025. However, the bio/pharma IPO activity remains far below its historical peak in 2020/2021. BPIQ recorded 15 IPOs in H1 2026, up 114% from seven in H1 2025. This was the highest first-half total since 2021, but only narrowly above the 14 IPOs recorded in H1 2022 and still far below the 61 recorded in H1 2021. Quarterly Activity Shows a Gr

H1 2026 private bio/pharma funding reached its highest total amount invested of the past three years, but the number of funding events declined by almost 33%. Total capital increased slightly compared with H1 2024 and H1 2025, while funding activity remained well below prior-year levels. This points to an investment environment where capital is still available, but fewer companies are securing it. In total, private companies raised approximately $20.3B across 366 funding even

BPIQ has released its H2 2026 Big Movers list, highlighting biotech catalysts with the greatest potential to drive meaningful stock moves. The list includes 18 Big Movers and 79 Suspected Movers. Suspected Movers are catalysts BPIQ identifies as having significant stock-move potential. Big Movers are near-term Suspected Movers where options-implied volatility confirms that the market is pricing in a large move. Elite and APEX subscribers can also see whether a Big Mover is de

Summary

BPIQ’s June 2026 Hedge Fund Stock Picks highlight three biopharma names with different catalyst profiles. This Pro version features the full CLDX pick, including its later-stage immunology setup, pivotal data ahead, and downloadable PDF report.

For June 2026, BPIQ’s Hedge Fund Stock Picks highlight three biopharma names with very different profiles: Celldex Therapeutics, ORIC Pharmaceuticals, and Compass Therapeutics.

ASCO 2026 was not only about individual readouts. Across five days, the meeting showed where oncology innovation is moving next: more targeted, more biomarker-driven, and increasingly built around complex therapeutic platforms. From BPIQ’s lens, several technology themes stood out. ADCs Stayed at the Center of Oncology Antibody-drug conjugates remained one of the most active modalities across the meeting. Nectin-4 was especially visible, with Corbus, Eli Lilly, and Bicycle Th

ASCO 2026 delivered important updates across hematologic malignancies, lung cancer, breast cancer, gastrointestinal cancers, melanoma, and several rare and difficult-to-treat tumors. Across the meeting, ADCs, bispecific antibodies, cell therapies, radioligand approaches, and increasingly precise biomarker-driven strategies remained at the center of oncology innovation. One presentation stood above the rest. During the Day 3 Plenary Session, Revolution Medicines presented what

Summary Since 2023, BPIQ model portfolios built around biopharma hedge fund consensus holdings have consistently and significantly outperformed the biotech benchmarks XBI and IBB. Background After extensive back-testing to find to identify the best strategies for using consensus holdings of top institutional investors to consistently beat the biotech benchmarks, we launched our first consensus-based portfolio (Top 20s) on 4/1/2023. By 9/30/2023, we applied the hedge fund favo

With the latest hedge fund filings incorporated into our portfolio targets, many subscribers ask a similar question: Why does BPIQ maintain multiple portfolio strategies instead of a single portfolio? The answer is simple. While all of our core portfolios are built from the same foundation, top holdings and consensus positions of biotech-focused hedge funds, portfolio construction matters. As discussed in our recent blog, consensus is the signal, structure is the edge. Years